JP2017528457A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528457A5
JP2017528457A5 JP2017512783A JP2017512783A JP2017528457A5 JP 2017528457 A5 JP2017528457 A5 JP 2017528457A5 JP 2017512783 A JP2017512783 A JP 2017512783A JP 2017512783 A JP2017512783 A JP 2017512783A JP 2017528457 A5 JP2017528457 A5 JP 2017528457A5
Authority
JP
Japan
Prior art keywords
dosage form
unit dosage
abiraterone acetate
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528457A (ja
Filing date
Publication date
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed filed Critical
Priority claimed from PCT/US2015/050889 external-priority patent/WO2016044701A1/en
Publication of JP2017528457A publication Critical patent/JP2017528457A/ja
Publication of JP2017528457A5 publication Critical patent/JP2017528457A5/ja
Pending legal-status Critical Current

Links

JP2017512783A 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法 Pending JP2017528457A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
US14/707,922 2015-05-08
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (2)

Publication Number Publication Date
JP2017528457A JP2017528457A (ja) 2017-09-28
JP2017528457A5 true JP2017528457A5 (enExample) 2018-10-18

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512783A Pending JP2017528457A (ja) 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法

Country Status (17)

Country Link
EP (1) EP3193857A4 (enExample)
JP (1) JP2017528457A (enExample)
KR (2) KR102491439B1 (enExample)
CN (1) CN106687112A (enExample)
AP (1) AP2017009804A0 (enExample)
AU (1) AU2015317466A1 (enExample)
BR (1) BR112017003219A2 (enExample)
CA (1) CA2958316A1 (enExample)
CO (1) CO2017002472A2 (enExample)
EA (1) EA201790650A1 (enExample)
IL (1) IL250270B (enExample)
MD (1) MD20170048A2 (enExample)
MX (1) MX2017003525A (enExample)
PH (1) PH12017500239A1 (enExample)
SG (1) SG11201701139YA (enExample)
TN (2) TN2017000098A1 (enExample)
WO (1) WO2016044701A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018187728A1 (en) 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS
DK3935068T3 (da) 2019-03-06 2023-12-04 Propella Therapeutics Inc Abirateron-prodrugs
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
WO2022174134A1 (en) 2021-02-15 2022-08-18 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595984A (en) * 2009-04-24 2014-04-30 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
CN105246598B (zh) * 2013-03-15 2019-09-13 太阳药业环球公司 乙酸阿比特龙酯制剂

Similar Documents

Publication Publication Date Title
JP2017528457A5 (enExample)
ES2742525T3 (es) Composiciones de corticosteroides administradas oralmente
JP3145111B2 (ja) 炎症性腸疾患処置用経口組成物
EP2903620A1 (en) Progesterone containing oral dosage forms and kits
WO2003000263A1 (en) Rapid onset formulation
JP2020530832A (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
EP3911304A1 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
WO2013134348A1 (en) Controlled-release solid dosage forms of mesalamine
JP2017517551A5 (enExample)
CN103316026B (zh) 含芬特明和托吡酯的联合产品及其制备方法
CN113018273A (zh) 一种固体制剂及其制备方法和用途
JP2010538062A5 (enExample)
CN105007902A (zh) 包含大量的两种丸粒的多颗粒药物组合物
JP2011506607A5 (enExample)
CN104510853B (zh) 一种治疗妇女痛经的中药有效部位组合物及其用途
JP2007529564A5 (enExample)
CN105106250B (zh) 一种灵芝总三萜组合物及其制备方法
US20230172875A1 (en) Extended release liquid compositions of guaifenesin
CN105663063B (zh) 甘草酸二铵和恩替卡韦的复方微丸片及其制备方法
CN104546733A (zh) 一种苯丙哌林掩味微丸
JP2016504390A5 (enExample)
CN101371825B (zh) 以丙酸氟替卡松为活性成分的口腔粘贴片
CN101371844B (zh) 以糠酸莫米松为活性成分的治疗口腔溃疡的粘贴片
TW200817012A (en) Peroral medicament form for contraception
WO2017100246A1 (en) Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof